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Abstract
Altered metabolic regulation has long been observed in human cancer and broadly used in the
clinic for tumor detection. Two recent findings—the direct regulation of metabolic enzymes by
frequently mutated cancer genes and frequent mutations of several metabolic enzymes themselves
in cancer—have renewed interest in cancer metabolism. Supporting a causative role of altered
metabolic enzymes in tumorigenesis, abnormal levels of several metabolites have been found to
play a direct role in cancer development. The alteration of metabolic genes and metabolites offer
not only new biomarkers for diagnosis and prognosis, but also potential new targets for cancer
therapy.
Introduction
Otto Warburg observed more than 80 years ago that tumor cells have altered metabolic
regulation; despite having an increased uptake of glucose, tumor cells produce much less
ATP than expected from a complete tricarboxylic acid (TCA) cycle coupled to oxidative
phosphorylation, and instead accumulate a significant amount of lactate [1–4]. Although the
molecular mechanisms and significance of this shift to aerobic glycolysis in tumor cells,
commonly known as the Warburg Effect, remain poorly understood, enhanced glucose
uptake provides the basis for 18FDG-PET technology which has been widely used clinically
for tumor detection by injecting patients with a radio-labeled glucose analog, 2(18F)-
fluoro-2-deoxy-D-glucose (FDG), followed by imaging with positron emission tomography
(PET).
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Despite its long history and broad clinical relevance, relatively little progress has been made
over past four decades in understanding how metabolism is altered in tumor cells and
whether this alteration contributes to, or is mere consequence of, tumorigenesis. This is
largely due to the fact that cancer research during this period has been focused on genetic
mutations in human cancer which, until recently, were not known to target genes encoding
for metabolic enzymes. Intensive studies on the PI3K-AKT-PTEN-mTOR tumor
suppression pathway, which is frequently altered in many types of cancers, led to the
realization that its control of cell growth is achieved in part through sensing and regulating
cellular energy metabolism [5–7]. Two lines of evidence—the direct regulation of metabolic
genes by known cancer genes and the discovery of mutations of metabolic genes in cancer—
have recently been developed that support the theory where, at least in these two cases,
altered metabolism contributes to, as opposed to occurs as a consequence of, tumorigenesis.
In this review, we will focus on discussing these two lines of scientific inquiry.
1. Classical cancer genes directly regulate metabolic enzymes
The levels of a number of metabolic enzymes are altered in different types of human tumors.
Yet, in most of these cases, the molecular mechanisms underlying their oncogenic
alterations remain to be elucidated. Below, we discuss several cases where changes in the
expression of metabolic enzymes or transporters have been linked directly, either genetically
or biochemically, to the function of frequently mutated cancer genes (Table 1).
1.1 Oncogenic activation of KRAS pathway upregulates GLUT1 and glucose uptake
The classical oncogenes KRAS and BRAF, a pair of effectors in the same signaling pathway
which are frequently mutated in a mutually exclusive pattern in a variety of human tumors,
have been shown to contribute to the metabolic dysregulation of cancer cells, in part, by
stimulating the increased expression of GLUT1, the gene encoding for glucose transporter 1
[8, 9]. GLUT1 is the ubiquitous mammalian glucose transporter, and it is physiologically
increased in the presence of hypoglycemia. In a serial analysis of gene expression (SAGE),
GLUT1 was identified as one of three genes that are consistently up-regulated in isogenic
colorectal cancer cells with KRAS or BRAF mutations [9]. Supporting a genetic link
between oncogenic activation of KRAS/BRAF and upregulation of GLUT1, long-term
glucose deprivation of cells with wild-type KRAS and BRAF genes developed constitutive
expression of the GLUT1 gene at elevated levels and, notably, a small fraction of them
acquired activating mutations in KRAS or BRAF genes [9]. Although the actual mechanism
of KRAS/BRAF mediated GLUT1 upregulation remains to be determined, particularly
whether it is mediated via an HIF-dependent or –independent process [9, 10], the
upregulation of GLUT1 increases glucose uptake, a phenomena seen broadly in many types
of tumors. Besides its potential role in facilitating tumor initiation, GLUT1 upregulation
could also promote the survival of tumor cells in hypoglycemic and hypoxic environments
thereby indirectly increasing the proliferative and invasive phenotypes of cancer cells.
Supporting this hypothesis, a clinical study recently found a correlation between GLUT1
expression and metastases in patients with advanced cervical cancer, emphasizing the
immediate link between cancer cell metabolism and phenotype [11].
1.2 Myc and HIF activates LDH-A gene expression
The Myc oncogene encodes a transcription factor and is frequently amplified in many types
of human tumors, while HIF-1α, also a transcription factor, is elevated in different types of
tumors resulting from loss-of-function mutations targeting its negative regulator, the Von
Hippel-Lindau (VHL) tumor suppressor. Both Myc and HIF-1α can bind directly to and
activate the expression of lactate dehydrogenase A (LDHA) [12–14]. HIF-1α accomplishes
this through binding a hypoxia response element (HRE) in the LDHA promoter, while Myc
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binds an upstream E-box [13, 14]. LDH is a homo- or heterotetrameric enzyme that is
composed of two subunits, A and B, encoded by two distinct genes, LDHA and LDHB,
resulting in five different isozymes depending on the ratio of the A and B subunits. While
the LDH enzyme can catalyze both the forward and backward conversion of pyruvate to
lactate, the two subunits have distinct kinetics with LDHA kinetically favoring the forward
and LDHB promoting the backward reaction. It has long been known that many tumor types
express high levels of LDHA [15]. Clinically, elevated LDH levels have been correlated
with poor prognosis and resistance to chemotherapy and radiotherapy. Inhibition of LDHA
by either RNA interference or pharmacological agents block tumor progress in vivo [16–18],
supporting an important role of elevated LDHA for tumorigenesis and a pathological
significance of LDHA gene upregulation by Myc and HIF-1α oncogenes.
1.3 Myc activates GLS1 gene expression and sustains elevated glutaminolysis
Renewed interest in the Warburg effect has focused attention in cancer metabolism research
on the enzymes and metabolic pathways linked to lactate production, including
glutaminolysis, whereby glutamate is catabolized to generate ATP and lactate. A key
enzyme involved in glutaminolysis is glutaminase, an amidohydrolase that converts
glutamine to glutamate. The human genome contains two glutaminase genes, GLS1 (also
known as GLS) and GLS2, and the expression of both genes have been found to be
regulated by two frequently mutated cancer genes, one (GLS1) by the Myc oncogene and
the other (GLS2) by the p53 tumor suppressor.
The first evidence linking the oncogenic function of Myc to the regulation of glutaminase
and cellular glutaminolysis came from the observation that knocking down Myc in a tumor
cell line with elevated Myc expression led to significant reduction of glutamine consumption
[19]. A search for Myc-regulated mitochondrial proteins subsequently identified GLS1 as a
target of Myc [20]. Instead of binding to and activating GLS1 gene expression, Myc
indirectly regulates the expression of GLS1 by suppressing two microRNA (miRNA),
miR-23a and miR-23b, that target the 3’untranslated region (UTR) of GLS1 gene. A
survival benefit for tumor cells is achieved by this Myc-stimulated GLS1 gene expression
via increased glutaminolysis leading to the replenishment of TCA cycle intermediates
(anaplerosis). Supporting the notion that elevated glutaminase activity is important for the
viability of tumor cells was the finding that pharmacological inhibition of a mouse splicing
variant of GLS1, Glutaminase C (GAC), inhibits malignant transformation by RhoGTPases
and the growth of xenografted tumors [21].
1.4 p53 activates the expression of GLS2 and TIGAR genes in response to oxidative
stresses
As a transcription factor, p53 regulates the expression of many genes to fulfill its tumor
suppressor function in response to various genotoxic stresses such as DNA damage,
oncogenic stimulation, nutrient deprivation, and hypoxic conditions. Although most well-
characterized targets of p53 are involved in either cell cycle regulation or apoptosis, recent
studies have identified several metabolic enzymes as the targets of p53 [22]. The first
reported metabolic gene as a potential target of p53 was type II hexokinase (HK2), which
contains two putative p53 binding elements in its promoter [23]. The functional significance
of p53-mediated HK2 activation remains to be elucidated. In a search for novel targets of
p53 by microarray, TIGAR (TP53-induced glycolysis and apoptotic regulator), was
identified and shown to encode a previously uncharacterized protein with regions
homologous to the catalytic domain of fructose 2, 6-bisphosphatase (FBPase2) [24]. The
enzyme activity of TIGAR in hydrolyzing fructose-2,6-bisphosphate (F-2,6-BP), a key
regulatory metabolite involved in sensing energy status, to fructose-6-phosphate (F6P), was
subsequently validated [25]. Induction of TIGAR, like elevated FBPase2, reduces the level
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of F-2,6-BP, which acts as an allosteric activator of phosphofructokinase (PFK). This
process results in the inhibition of glycolysis and activation of the pentose phosphatase
pathway (PPP) leading to increased levels of glutathione (GSH), a key antioxidant, and the
lowering of intracellular reactive oxygen species (ROS).
In addition to TIGAR, glutaminase 2 (GLS2), but not GLS1, is another p53 target gene [26,
27]. As well as increasing the production of mitochondrial respiration and ATP production,
p53-activated GLS2 expression was also found to elevate the levels of GSH and reduce
reactive oxygen species (ROS) in a p53- and GLS2-dependent manner. Knocking down
either p53 or compromised this GSH-dependent antioxidant system and lead to ROS
accumulation. These findings suggest that p53 may constitute a metabolic checkpoint
pathway, in addition to its roles in mediating DNA damage or oncogene checkpoint
pathways, by mediating the cellular response to oxidative stress.
It remains a puzzle as to why two GLS enzymes, both localizing in the mitochondria and
catalyzing the same reaction, are regulated so differently; one by a proliferation-stimulating
oncogene and one by a growth inhibitory tumor suppressor. Several possibilities have been
proposed to reconcile this enigma [28], including the difference between two GLS proteins
in their kinetics of activation by phosphate and inhibition by product glutamate, or having
additional and different properties such as interacting with different proteins. Further studies
are needed to determine the different roles and regulation of these two GLS genes in
tumorigenesis.
1.5 Myc promotes alternative splicing of PKM2
Given the presence of large number of Myc targets in vivo, it is perhaps not surprising to see
that Myc regulates yet another metabolic enzyme, PKM2, through the transcriptional
activation of its splicing factors. The human genome encodes two distinct pyruvate kinase
(PK) genes, PKLR and PKM2, that express four PK isoforms: L, R, M1 and M2 [29]. The L
and R isoforms are expressed specifically in liver and red blood cells, respectively, from the
PKLR gene through the use of different promoters [30]. Conversely, M1 and M2 are
expressed in most adult tissues and during embryogenesis, respectively, from the PKM2
gene by alternative RNA splicing [31]. Notably, PKM2 is highly expressed in tumors of
many different types [32, 33]. The significance of switching from constitutively active
PKM1 to the FBP-regulated PKM2 isoform in tumor cells is not clear at present. Two
different roles have been proposed, one focusing on its function in glycolysis in the
cytoplasm, and one proposing a glycolysis-independent function in the nucleus. The former
view has been proposed for some time, and holds that the switching from constitutive highly
active PKM1 to the FBP-regulated, less active PKM2 would decrease the conversion of
phosphoenolpyruvate (PEP) to pyruvate which normally enters mitochondria to serve as the
precursor for the TCA cycle. As the result of this decreased PK activity, cells would
accumulate more glycolytic intermediates, many of which are used for biosynthetic
reactions for cell growth and division, including fatty acids, DNA and RNA [34]. The latter
role was spurred by a surprising finding that PKM2, but not PKM1, can enter the nucleus
where it acts as a transcriptional co-activator with HIF-1α or β-catenin [35, 36], potentially
expanding the function of PKM2 beyond glycolysis in the cytoplasm. The mechanism
underlying the switch of PKM1–PKM2 alternative splicing remained elusive for a long time,
but was recently found to be regulated, in part, by Myc [37]. In this study by David et al.,
three heterogenous nuclear ribonucleoprotein (hnRNP) proteins, hnRNPA1, hnRNPA2 and
hnRNPI (also known as PTB), were found to bind repressively to sequences flanking exon 9
of PK gene, resulting in exon 10 inclusion and the production of PKM2 mRNA. The
expressions of the genes encoding for these three hnRNP are upregulated by Myc, linking
the function of Myc oncogene to the altered activity of this major metabolic enzyme [37].
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2. Eight metabolic genes encoding for four metabolic enzymes are mutated
in human cancer
The strongest evidence supporting the notion that altered metabolism directly contributes to
tumorigenesis comes from the finding that eight genes, FH, SDHA, SDHB, SDHC, SDHD,
SDHAF2, IDH1 and IDH2, encoding for the subunits of four different metabolic enzymes,
fumarate hydratase (FH), succinate dehydrogenase (SDH), isocitrate dehydrogenase 1 and 2
(IDH1 and IDH2), are mutated, both germinally and somatically, in a number of types of
human cancers (Table 2). In addition, although found in only one type of tumor (ovarian
carcinoma) and low in prevalence (8 cases out of more than 300), somatic mutations in the
L2HGDH gene encoding for L-2-HG dehydrogenase may be pathologically significant in
tumorigenesis given the emerging oncogenic activity of its substrate, 2-HG, when
accumulated (see below) [38]. We will first review the clinical features of these mutations
and then focus the discussion on a newly emerging mechanism that may underline the tumor
mutations targeting these four enzymes that are otherwise unrelated in their catalytic
properties.
2.1. Loss of function mutations target all five subunits of SDH in cancer and occur in a
mutually exclusive pattern
The first major metabolic gene found to be mutated in human cancer was the SDHD gene,
encoding for a subunit of succinate dehydrogenase (SDH), in familial paraganglioma, a
relative benign head and neck tumor [39–41]. SDH is unique in that it is both a TCA cycle
enzyme as well as a component of the electron transport chain. It is confined to the inner and
outer mitochondrial membranes, and catalyzes the oxidation of succinate to fumarate with
the concomitant reduction of ubiquinone to ubiquinol. Like bacterial SDH, human SDH is
composed four subunits encoded by four distinct genes, SDHA, SDHB, SDHC and SDHD,
and is activated by a newly discovered assembly factor, SDHAF2 (also known as SDH5)
[42]. Following the initial finding of SDHD mutations in tumor, both the SDHB and SDHC
genes were found to be mutated in renal cell carcinoma and papillary thyroid carcinoma, and
reduced expression of SDHD was noted in gastric and colorectal carcinoma [43]. More
recently, mutations of both remaining SDH genes, SDHAF2 and SDHA, were also identified
in familial and sporadic paraganglioma, pheochromocytoma, and gastrointestinal stromal
tumors [42, 44–46]. Hence, mutations in all five SDH genes have been linked to tumor
development [47]. Thus far, SDH mutations have been reported in more than 650 tumor
specimens, and there has been no report for the occurrence of mutations targeting two
different SDH subunits in the same tumor. This result indicates that a loss of function
mutation in any of the five subunits of the SDH enzyme carries the same functional
consequence in contributing to tumorigenesis, likely by causing the reduction or inactivation
of the function of SDH holoenzyme in the cell.
2.2 Loss of function mutations targeting FH gene are found in different type of tumors
Fumarate hydratase (FH, also known as fumarase) catalyzes the reversible hydration/
dehydration of fumarate to malate. The human genome contains a single FH gene that
expresses two forms of fumarase via the use of different translation start sites: a longer form
containing a mitochondrial localization signal that participates in the TCA cycle, and a short
form localized to the cytoplasm that participates in purine synthesis and the urea cycle.
Human FH holoenzyme is very similar to bacterial fumarase C, which functions as a
homotetramer with an active site comprised of amino acid residues from three of the four
subunits [48]. Mutations targeting the FH gene in tumors were first found in inherited
uterine fibroids, skin leiomyomata, and papillary renal cell cancer, [49] and subsequently in
leydig cell tumors [50]. Thus far, FH mutations have been reported in more than 300 tumors.
Like SDH mutations, all functionally characterized FH mutations resulted in either a
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complete loss or reduction of FH activity [50, 51], indicating a tumor suppressive function
of the FH gene.
2.3 IDH1 and IDH2 are frequently mutated in human cancer
A cancer genome project made a surprising discovery in 2008 in the form of recurring
mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) in malignant gliomas
[52]. This finding was quickly confirmed by a flurry of studies involving directed
sequencing of IDH1 and its homologue IDH2 which cumulatively established that IDH1 and
less frequently IDH2 genes are mutated in more than 75% of grade 2 – 3 gliomas and
secondary glioblastomas [53]. A separate cancer genome project comparing the genome
from leukemic cells in a patient with acute myeloid leukemia (AML) to the normal skin cells
of the same individual also identified a mutation in the IDH1 gene in AML in 2009 [54].
Subsequent direct sequencing in a large number of AML samples established that the IDH1
or IDH2 genes are mutated in about 20% of AML [53]. More recently, IDH1 and IDH2
genes were found to be mutated in thyroid carcinomas (16%) [55, 56], chondrosarcoma
(56%) [57] and enchondroma (85%) [58, 59]. IDH1 and IDH2 mutations have also been
reported in a limited number of samples of several additional types of tumors at lower
frequency, including melanoma (4/39) [60], paraganglioma (1/131) [61], prostate cancer
(2/75), B-acute lymphoblastic leukemias (B-ALL, 1/60) [62], angioimmunoblastic T-cell
lymphoma (AITL, 40%) [63], and intrahepatic cholangiocarcinoma (23%) [64]. IDH1 and
IDH2 represent by far the most frequently mutated metabolic genes in human cancer.
2.4 IDH1 and IDH2 mutations exhibit six unique biochemical and clinical features
(1) IDH1/2 mutations are all heterozygous and predominantly target a single amino acid
substitution, Arg132 in IDH1 or corresponding Arg172 in IDH2, and Arg140 in IDH2,
indicating a gain-of-function. (2) IDH1 and IDH2 mutations occur in a mutually exclusive
manner, indicating a common underlying biochemical mechanism. (3) IDH1/2 mutations are
all somatic, and no germ-line mutation has been reported, consistent with a possible
dominant effect of the mutation on cell growth. (4) IDH1/2 mutations occur in a highly
restricted tumor spectrum, frequently arising in grade 2–3 gliomas and secondary
glioblastomas, but not in primary GBM, in cytogenetically normal AML, but not other
subtypes of AML. This feature suggests that the contribution of IDH1/2 mutations to
tumorigenesis may be linked to cell fate determination or cell differentiation. (5) IDH1/2
mutations are only found in adult, not in pediatric, glioma or AML patients. (6) IDH1
mutations are associated significantly with better prognosis in glioma patients. The slower
growing and less invasiveness of IDH-mutated tumors is consistent with the notion that
mutant IDH enzymes, in addition to their tumor-promoting effects, may also cause growth
inhibition at the same time. These unique properties of IDH1/2 mutation not only raise
important mechanistic, biological, and clinical questions about the role of this metabolic
pathway in tumorigenesis, but also provide a unique opportunity to develop a strategy for
therapeutic intervention based upon the premise of employing small molecular inhibitors
against these tumors which may be identifiable in a non-invasive manner using their
chemical and clinical characteristics.
3. Mutations in FH, SDH and IDH genes impair the function of α-KG and
inhibit α-KG-dependent dioxygenases
Several hypotheses have been proposed to explain the mechanism underlying the
contribution to tumorigenesis by the mutations targeting the FH, SDH, and IDH enzymes
since the first report of SDHD gene mutations in tumors. For traditional cancer genes,
experimental increased or decreased expression usually results in detectable changes in
cellular phenotype such as increased proliferation, survival, migration, or molecular changes
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associated with one of these cellular features. However, none of these commonly observed
hallmarks have been consistently found to associate with the ectopic expression of tumor-
derived mutants of metabolic genes in cultured cell systems. Given the same subcellular
localization of both FH and SDH enzymes (and later IDH2) in mitochondria, and function in
the TCA cycle, early attention on the elucidation of biochemical mechanisms underlying the
mutations in metabolic genes was focused on mitochondrial dysfunction in cells with SDH
and FH mutations [65]. Inactivating mutations in FH and SDH were originally hypothesized
to cause mitochondrial dysfunction-induced tumorigenesis by (1) abrogating the
mitochondria’s ability to trigger apoptosis, (2) generating ROS that damage both cellular
and mitochondrial DNA, and (3) stabilizing HIF-1α [66]. The finding that IDH1, the most
frequently mutated metabolic gene of the eight, encodes a protein that localizes in the
cytoplasm indicates that the effects of metabolic gene mutations on tumorigenesis likely
goes beyond direct mitochondrial dysfunction. We will focus the remainder of our
discussion in this review on a newly emerging mechanism—impaired activity of α-KG-
dependent dioxygenases and altered epigenetic control—that may be common to the
mutations of all eight metabolic genes.
3.1 HIF-1α, a substrate of α-KG-dependent prolyl hydroxylases (PHDs), is elevated in FH
and SDH mutated cells
α-ketoglutarate (α-KG)-dependent dioxygenases (also known sometimes as oxygen
transferases) incorporate both atoms of molecular oxygen into their substrates (Figure 1A).
They should not be confused with oxidases, which reduce both oxygen atoms to water, or
monooxygenases, which transfer one oxygen atom to the substrate and one to water. Fe(II)/
α-KG-dependent dioxygenases are present in all living organisms and catalyze
hydroxylation reactions on a diverse set of substrates including proteins, alkylated DNA and
RNA, lipids, antibiotics, and recently discovered 5-methylcytosine of genomic DNA [67–
69] (Figure 1B). These enzymes require Fe(II) as a cofactor metal, and utilize α-KG as a co-
substrate to catalyze a reaction in which one oxygen atom from molecular oxygen (O2) is
attached to a hydroxyl group in the substrate (hydroxylation), while the other is taken up by
α-KG leading to the decarboxylation of α-KG and subsequent release of carbon dioxide
(CO2) and succinate.
Studies into the mechanism behind how mutations in SDH and FH trigger elevated levels of
HIF-1α provided the first evidence that mutations in metabolic enzymes lead to the direct
inhibition of α-KG-dependent dioxygenases [70]. It was first described that inhibition or
mutation of SDH resulted in an accumulation of its substrate, succinate, which binds directly
to and inhibits the activity of PHD, leading to increased stability and elevated levels of both
HIF-1α and HIF-2α [71]. Similarly, fumarate, the substrate of FH which is accumulated in
FH-deficient cells, was also found to inhibit PHD leading to elevated levels of HIF-1α and
HIF-2α proteins [72]. Addition of α-KG efficiently relieves the inhibition of PHD by either
fumarate or succinate, thereby restoring the hydroxylation of HIF proteins[72]. This finding
provided the first evidence that the activity of succinate and fumarate is due to the
antagonizing of α-KG dependent processes and negatively regulating α-KG-dependent
dioxygenases such as PHDs.
3.2 IDH1/2 mutants display simultaneous loss and gain of function in the production of α-
KG and 2-hydroxyglutarate (2-HG)
IDH enzymes catalyze the oxidative decarboxylation of isocitrate to produce α-KG. The
human proteome contains three distinct IDH enzymes whose activities are dependent on
either nicotinamide adenine dinucleotide phosphate (NADP+-dependent IDH1 and IDH2) or
nicotinamide adenine dinucleotide (NAD+-dependent IDH3). Both IDH2 and IDH3
enzymes are localized in the mitochondria, while IDH1 is localized in the cytoplasm and
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peroxisomes[73]. α-KG plays critical roles in four different metabolic and cellular
pathways: (1) as an intermediate in the TCA/Krebs Cycle for energy metabolism, (2) as a
precursor of glutamine formation for the amino acid synthesis, (3) as a nitrogen transporter
for the urea cycle and detoxification, and (4) as a co-substrate for Fe(II)/α-KG-dependent
dioxygenases in oxygen sensing and hydroxylation of various protein and nucleic acid
substrates such as histones and DNA. This last function of α-KG has gained very little
attention until now, and is emerging as an important regulatory mechanism in the epigenetic
control of cellular processes.
The first biochemical change identified in tumor-derived mutant IDH1 and IDH2 was that
all mutants of IDH1 and IDH2 lose their catalytic activity in the production of α-KG [74,
75]. This finding led to the examination of the activity of α-KG-dependent PHDs, and the
finding that in cultured cells expressing mutant IDH, similarly to cells expressing mutant FH
and SDH, the steady state level of HIF-1α was increased and could be reversed by the
treatment of cells with cell-permeable α-KG [74]. This finding supports a rate-limiting role
for α-KG in vivo for the α-KG-dependent dioxygenases such as PHDs, and raises the
possibility that drugs mimicking α-KG may serve as therapeutic agents for tumors that
harbor IDH1 mutations [74].
Subsequently, Dang et al. made a surprising discovery that, in addition to abolishing its
normal activity in α-KG production, mutant IDH1 gained a new activity—catalyzing the
reduction of α-KG to produce D-2-hydroxyglutarate (D-2-HG, also known as R-2-HG)[76].
In IDH1 mutated glioma, D-2-HG accumulates to astonishingly high levels of
approximately 5 – 35 µmole/g (or 5 – 35mM). Efforts are currently underway toward the
development of magnetic resonance spectroscopy (MRS) to detect non-invasively the
accumulation of 2-HG in glioma patients [77]. D-2-HG was also found to accumulate in
IDH1- and IDH2-mutated AML [78–80] and enchondroma [58]. A significant level of D-2-
HG was even detected in the peripheral blood of AML patients carrying a mutation in the
IDH1 gene [79]. In fact, ectopic expression of all tumor-derived mutations targeting three
hot spots, Arg132 in IDH1, Arg140 and Arg172 in IDH2, have been found to produce and
accumulate D-2-HG [81–83]. Accumulation of a different enantiomer, L-2-HG (also known
as S-2-HG), has previously been linked to L-2-hydroxyglutaric aciduria (L-2HGA), a rare
metabolic disorder that is caused by a defect in L-2-HG dehydrogenase (L2HGDH) in
mitochondria and is associated with psychomotor retardation, progressive ataxia,
leukodystrophy[84, 85], and in a few cases increased risk of developing brain tumors [19].
Neither enantiomer of 2-HG has been found to have any physiological function, and both
can be considered as metabolic waste that, if not removed, are toxic or tumorigenic to cells.
3.3 2-HG is a competitive inhibitor of α-KG-dependent dioxygenases that include both
histone and DNA demethylases
In the active site of α-KG-dependent dioxygenases, α-KG uses two oxygen atoms from the
α-keto carboxyl end, one from its C-1 carboxylate and one from its C-2 ketone, to
coordinate Fe(II) and two oxygen atoms linked to C-5 at the acetate end to interact with
conserved residues in the dioxygenases. 2-HG and α-KG are structurally similar, except for
the oxidation state at C-2 on which the oxygen in α-KG is replaced by a hydroxyl group in
2-HG, suggesting the possibility that 2-HG may bind to these enzymes and function as an
antagonist of α-KG. This hypothesis was later confirmed by showing that 2-HG is a
competitive inhibitor of multiple α-KG-dependent dioxygenases in vitro, including collagen
prolyl hydroxylase (CPHs) involved in collagen processing and endostatin production,
PHDs and factor inhibiting-HIF (FIH) involved in HIF-α regulation, several histone lysine
demethylases (KDMs), AlkB homologue (ALKBH) involved in DNA repair, γ-butyrbetaine
hydroxylase (BBOX1) involved in carnitine biosynthesis, and DNA hydroxylases in the
form of ten-eleven translocases (TETs) [82, 86]. In vivo, ectopic expression of mutant IDH1
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or IDH2 in cultured cells or mutations targeting IDH1 in human gliomas resulted in the
decrease of endostatin (the product of CPHs), increase in methylation on multiple histone
lysine residues, and inhibition of hydroxylation of 5-methylcytosine (5hmC). More direct
evidence supporting an antagonist interaction between α-KG and 2-HG came from the
crystal structural analysis of several α-KG-dependent dioxygenases bound with 2-HG which
revealed that D-2-HG binds to the active site in close proximity to Fe(II) and adopts a nearly
identical orientation as α-KG.
2-HG appears to be a rather weak competitive inhibitor of α-KG though. For some α-KG-
dependent dioxygenases such as C.elegans KDM7A and TET DNA hydroxylases, as much
as a 100 fold elevation D-2-HG is needed to achieve more than 50% inhibition [82].
Comprehensive in vitro assays indicate that the half-maximal inhibitory concentration (IC50)
varies significantly among different α-KG-dependent dioxygenases, with histone H3K9/
H3K36 dual specificity demethylases KDM4A/JMJD2A and KDM4C/JMJD2C being the
most sensitive (IC50 = 24 µM and 79µM, respectively), and PHD2 and BBOX being very
resistant (IC50 = 13 mM and 4 mM, respectively) [86]. Consistent for all enzymes that have
been examined, L-2-HG appears to be 3 to 15 times more potent than D-2-HG. Both the
significance and the mechanism of this higher potency are not clear at present. L-2-HG has
not been found to be associated with tumor development, and has been suggested to exhibit
possibly a kinetics that are different from D-2-HG [86].
3.4 Genetic evidence supports TET DNA hydroxylases as a pathologic target of 2-HG
Of the more than 60 estimated α-KG-dependent dioxygenases in mammalian cells [87],
TET proteins are the newest members [69, 88]. TET proteins catalyze a three-step iterative
oxidation reaction: converting 5mC to first to 5hmC, then 5hmC to 5-formylcytosine (5fC),
and finally 5fC to 5-carboxylcytosine (5caC) [88–91]. A subsequent decarboxylation of
5caC, by either a thymine-DNA glycosylase or other DNA repair enzyme, could then lead to
DNA demethylation. Inhibition of the TET family of DNA hydroxylases was demonstrated
both in vivo, in cells expressing mutant IDH1 or IDH2, and in vitro [81] [82]. Importantly,
there are two lines of genetic evidence that supports TET DNA hydroxylases as being
pathologically relevant targets of IDH1 mutations. First, promoter DNA methylation
profiling analysis has revealed that a subset of glioblastoma, known as the proneural
subgroup [92], are enriched for IDH1 mutations and display hypermethylation at a large
number of loci [93], suggesting a potential link between IDH1 mutation and increased DNA
methylation which could be explained by the 2-HG inhibition of TET activity. Second,
inactivating mutations of the TET2 gene were found in about 22% of AML cases [94, 95],
notably occurring in a mutually exclusive manner with that of IDH1/2 genes in AML [81].
Genetic evidence supporting the pathological relevance of other α-KG-dependent
dioxygenases to tumorigenesis driven by IDH1/2 mutations has not been reported at present.
A critical issue related to the significance of the IDH-TET regulation in tumor suppression is
the identification of specific targets whose expression is affected by IDH mutation induced
hypermethylation and which contribute to gliomagenesis are yet to be identified. Searching
for genes which are differentially methylated between tumors with mutated verse wild-type
IDH1/2 genes in both glioma and AML have yielded many potential candidates of IDH
targets [81, 92, 93, 96], but no clear pathway has emerged. An alternative model to this IDH
mutation-TET inhibition-promoter methylation-targeted gene axis is that broad and random
alterations in genomic methylation landscape create an epigenetic milieu which confers a
selective advantage to IDH mutant clones that facilitates oncogenesis. This may represent a
phenomenon of “epigenomic instability”, similar to the known "genomic instability" that is
associated with mutations targeting DAN repair pathway.
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3.5 Could fumarate and succinate also function as α-KG antagonists to negatively regulate
other α-KG-dependent dioxygenases besides PHDs?
Structurally, both succinate and fumarate are also similar to α-KG and 2-HG. They have the
same acetate end and include two oxygen atoms linked to C-5 that are used by α-KG and 2-
HG to interact with conserved residues in the dioxygenases. Such structural similarity
suggests that, in addition to PHDs, both fumarate and succinate in FH and SDH deficient
tumor cells may negatively regulate additional α-KG-dependent dioxygenases either by
competitive inhibition like 2-HG. Supporting this idea, yeast cells deficient for SDH
(sdh2Δ) accumulated succinate and had increased dimethylated H3K36. In vitro, succinate
was found to inhibit human H3K9 histone demethylase KDM4D/JMJD2D with an estimated
10 to 100 folds higher potency than required to compete with α-KG [97]. Further studies are
needed to extend this finding and to determine whether fumarate also compete with α-KG
and interferes with α-KG-dependent dioxygenases.
The similar structure and chemical properties of these three oncometabolites, 2-HG,
succinate, fumarate, combined with evidence that all three can antagonize α-KG raises the
interesting implication that the combined concentration of these three oncometabolites, as
opposed to the individual concentrations, may be the more relevant concentration to the
regulation of α-KG dependent dioxygenases and epigenetic stability in the cell. Considering
succinate is the product of α-KG-dependent dioxygenases, an alternative model would be
that the high levels of succinate accumulated in FH or SDH mutated cells inhibit the activity
of α-KG-dependent dioxygenases through product inhibition.
3.6 Accumulation of fumarate in FH-deficient cells causes aberrant succination of many
proteins, including antioxidant regulator, KEAP1
Very recently, a new function of fumarate—covalently attaching to cysteine residues—was
reported that is independent of its regulation of α-KG-dependent dioxygenases and is
significantly upregulated in FH-deficient cells [98, 99]. Fumarate can react spontaneously
with cysteine sulphydryl groups by a Michael reaction (nucleophilic addition of a carbanion
to an α,β-unsaturated carbonyl compound) to form a stable chemical modification of
protein, S-(2-succinyl) cysteine (2SC) with this reaction being named, a bit inconveniently
for this discussion, as succination [100]. Prompted by this finding and the accumulation of
fumarate in FH-deficient cells, Pollard and his colleagues examined the levels of succinated
proteins in both Fh1-deficient mouse embryonic fibroblasts (MEFs), and in an FH-deficient
HLRCC tumor cell line using antibodies recognizing 2SC [99]. Significantly higher levels of
2SC-modified proteins were found in both cell lines, but not in normal tissues or tumors not
associated with FH mutation. A large number of proteins are apparently succinated in FH-
deficient cells, making the aberrant succination a robust biomarker for the detection of FH-
deficient tissues. One target of fumarate modification, Kelch-like ECH-associated protein 1
(KEAP1), was identified and functionally characterized in a subsequent study [98, 101].
Two separate gene expression profiling studies between FH wild-type and deficient cells
identified the antioxidant pathway mediated by the nuclear factor (erythroid-derived 2)-like
2 (Nrf2) being one of the most significantly activated pathways in Fh1 null cells. The
principal regulator of NRF2 is KEAP1 which binds to and targets NRF2 for ubiquitylation
and degradation, and multiple cysteine residues in KEAP1 are critical for KEAP1 to interact
with NRF2. KEAP1 was found to be succinated at multiple cysteine residues in Fh1-
deficient, but not wild-type MEFs, and conversely repressed several NRF2 targets in wild-
type, but not Fh1-deficient cells. Feeding cells with cell-permeable fumarate increased the
expression of NRF2 proteins. These findings suggest that the aberrant modification of
cellular proteins by abnormally accumulated fumarate in FH-deficient cells can alter specific
cellular pathways, such as the NRF2-mediated oxidative stress response, and provide an
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example of a potentially pathological post-translational modification directly mediated by an
oncometabolite.
Conclusion
Over the past decade, we have seen a resurgence of interest in the study of tumor
metabolism inspired in part by the discovery of the direct regulation of metabolic enzymes
by frequently mutated classical cancer genes, and more immediately by the discovery of
tumor mutations targeting human metabolic enzymes. One unique aspect that differentiates
metabolic regulation from other cellular regulatory pathways which commonly involve
regulation at the level of gene expression and protein function, is that levels of metabolites
are not merely the product of metabolic enzyme activity, but can also play regulatory roles
to other enzymes. The study of three putative oncometabolites as discussed above (2-HG,
succinate, and fumarate) has taught us that the reach of these metabolites in the regulation of
cell activity can extend beyond metabolic enzymes to a potentially large number of α-KG
dependent dioxygenases which control diverse cellular processes from transcription to post-
translational modification. Like classical oncogenes, two of these three metabolites,
succinate and fumarate, perform important physiological function for normal cell
metabolism and only became oncogenic when their amount accumulated to abnormally high
levels. Rapid progress is being made in the development of mass spectrometry based
technology for the rapid detection and accurate quantification of metabolites in the field of
metabolomics. The discovery of 2-HG production by mutant IDH provides an excellent
example to illustrate the promise of this new technology. We can anticipate these
technological developments will significantly facilitate attempts to determine how the levels
of metabolites are changed both in physiologic stress responses, such as nutrient deprivation
and oxidative stress, as well as during tumor development.
The second unique aspect emerging from the study of mutant metabolic genes is that
changes in the levels of metabolites may link changes in extracellular conditions, the so-
called microenvironment, to gene expression. Such a principle has long been established in
bacterial metabolic regulation, but is only beginning to emerge in higher eukaryotic and
human cells. The finding that three oncometabolites can affect DNA and histone
methylation suggests that altered metabolites, besides acute and short-term responses to the
changes of nutrient conditions, may impact epigenetic control and cell fate determination
and differentiation. It is notable that direct genetic evidence for these three putative
oncometabolites is lacking, with most evidence supporting their pathophysiological role
being derived from cellular and biochemical studies thus far.
While the cellular signals leading to the regulation of metabolic genes by classical cancer
genes are relatively clear from decades of investigation into these cancer genes, it is less
clear what signals or stressors, besides mutation, would affect the intracellular levels of
oncometabolites. This concern is of immediate relevance to the feasibility of targeting
metabolic enzymes for cancer therapy. For example, could IDH mutant tumors remain
addicted to high levels of 2-HG and therefore be susceptible to inhibition of the 2-HG
producing mutation of IDH? If, like 2-HG, both fumarate and succinate are indeed
contributing to tumorigenesis by antagonizing α-KG, could α-KG itself be exploited as a
therapeutic agent for tumors with a mutation in the IDH, FH, or SDH genes? The study of
these oncometabolites offers the opportunity not only to understand how altered metabolism
contributes to tumorigenesis, but also to uncover the elusive link between cancer and other
metabolic diseases such as diabetes and obesity.
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• Classical cancer genes directly regulate metabolic enzymes.
• Genes encoding eight genes of four metabolic enzymes are mutated in cancer.
• Three oncometabolites inhibit α-KG dependent dioxygenases.
• Oncometabolites may link cancer genetics, epigenetics, and microenvironment.
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Figure 1. The substrates and regulation by metabolites of α-KG dependent dioxygenases
(A) A schematic diagram of hydroxylation reaction catalyzed by the α-KG dependent
dioxygenases. The substrates of this family of enzymes include both nucleic acids and
proteins. Five different amino acid residues, Proline (Pro), methyllysine (Lys),
methylargnine (Arg), Asparagine (Asn) and Aspartate (Asp), have been found to date to be
hydroxylated. Hydroxylation of both Arg and Lys occur only on the methylated, but not
unmodified residues. Four bases in DNA or RNA can be methylated by either enzyme
(DNA methyltransferase)-catalyzed methylation at C-3 position of cytosine (3-meC) or
alkylating agents on a variety positions of different bases. Hydroxylation of methylguanine
has been reported for bacterial AlkB, but not for human AlkB homologues (ABH).
(B) The currently known oncometabolites (2-HG, succinate, fumarate) act upon a wide
range of α-KG dependent dioxygenases both in the cytosol and in the nucleus. In addition to
the hydroxylation of protein and DNA substrates, a member of α-KG dependent
dioxygenases, fat mass and obesity (FTO) protein, can recognize and hydroxylate N6-
methyadenosine in nuclear RNA [102].
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Table 1
The regulation of metabolic enzymes by classical cancer genes.
Gene Target Metabolic Enzyme Mechanism Metabolic Function
p53 TP53-induced glycolysis and apoptosis regulator
(TIGAR)
Transcription ROS-induced apoptosis protection
Type II hexokinase (HK2) Transcription First committed step of glycolysis
Glutaminase 2 (GLS2) Transcription Reaction: Glutamine + H2O → Glutamate + NH3
Myc Lactate dehydrogenase A (LDH-A) Transcription Reaction: Pyruvate + NADH → Lactate + NAD+
miR-23a/b Transcription Glutaminase 1 (GLS1) expression
Heterogenous nuclear ribonucleoprotein A1/2/I
(hRNPA1/2/I)
Transcription Regulate alternative splicing of PKM2
AMPK Acetyl-CoA carboxylase (ACC) Phosphorylation Rate limiting enzyme in fatty acid synthesis
HMG-CoA reductase (HMGR) Phosphorylation Rate limiting enzyme in cholesterol synthesis
Phosphofructokinase-2 (PFK2) Phosphorylation Regulates PFK1 activity to balance glycolysis and
gluconeogenesis
Malonyl-CoA decarboxylase Phosphorylation Fatty acid biosynthesis
Glycogen synthase (GS) Phosphorylation Converts glucose into glycogen
Hormone sensitive lipase (HSL) Phosphorylation Mobilizes free fatty acids in adipose tissue, and free
cholesterol in endocrine tissue.
Akt Glycogen synthase kinase 3 (GSK3) Phosphorylation SREBP expression and fatty acid biosynthesis regulation.
Regulates GS.
TBC1 domain family member 4 (TBC1D4/
AS160)
Phosphorylation GLUT4 cell membrane translocation
Type II hexokinase (HK2) Phosphorylation First committed step of glycolysis
Phosphofructokinase-2 (PFK2) Phosphorylation Regulates PFK1 activity to balance glycolysis and
gluconeogenesis
mTOR Ribosomal protein S6 kinase beta-1 (S6K1) Phosphorylation Increased protein biosynthesis
KRAS ?Glucose transporter 1 (GLUT-1)? ?? Basal glucose transport across cell membranes
BRAF ?Glucose transporter 1 (GLUT-1)? ?? Basal glucose transport across cell membranes
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Table 2







Reaction catalyzed Somatic Tumor Types
or Tumor Syndromes1
Mutation Frequency2
IDH1 IDH1 (2q33.3) Isocitrate + NADP+ → Glioma3 Somatic, ~75%
Isocitrate α-KG + NADPH + CO2 Cartilaginous Tumors4 Somatic, ~75%
Dehydrogenase 1 AML5 Somatic, ~20%
Cytoplasm Thyroid Carcinoma6 Somatic, 16%
Peroxisome Melanoma Somatic, 4/39
Prostate Carcinoma Somatic, 2/75
IDH2 IDH2 (15q26.1) Isocitrate + NADP+ → Paraganglioma Somatic, 1/131
Isocitrate α-KG + NADPH + CO2 Cholangiocarcinoma11 Somatic, 23%
Dehydrogenase 2 Colorectal Carcinoma Somatic, 2/180
Mitochondria T-cell lymphoma12 Somatic, 45%
FH FH (1q42.1) Fumarate + H2O → HLRCC7 Germline: Autosomal Dominant
Fumarate Hydratase s-Malate MCUL8 Germline: Autosomal Dominant
Mitochondria Renal Cell Carcinoma Somatic, 1/3
Cytoplasm Melanoma Somatic, 1/14
Leydig cell tumor Germline Mutation+Somatic LOH,
2/29
Ovarian Cystadenoma9 Germline, 2/33
Leiomyoma LOH + Somatic Mutation, 1.3%
Lung Adenocarcinoma Somatic, 1.1%
SDH SDHA (5p15.33) Succinate + Ubiquinone → Familial Paraganglioma Germline: Autosomal Dominant
Succinate SDHB (1p36.1) Fumarate + Ubiquinol Merkel Cell Carcinoma Somatic, 2/7
Dehydrogenase SDHC (1q23.3) Paraganglioma LOH + Germline, 6/36
Mitochondria SDHD (11q23.1) Midgut Carcinoid LOH + Somatic, 2/18
SDHAF2 (11q12.2) GIST10 Germline, 3/34
Pheochromocytoma Germline, 4.4%
1
IDH1 and IDH2 mutations are grouped together due to their mechanistic similarity and exclusive occurrence in the tumors
2
For studies with sample number less than 100, the actual numbers, instead of percentages of mutation are given.
3
Glioma includes all WHOI-IV glioma.
4
Includes central enchondromas and chondrosarcomas, periosteal chondromas, and cartilaginous tumors associated with Maffuci and Ollier
syndrome.
5




HLRCC, Hereditary Leiomyoma with Renal Cell Carcinoma.













Oermann et al. Page 21
8




GIST, Gastrointestinal Stromal Tumor.
11
Intrahepatic cholangiocarcinoma only, no mutations were found in extrahepatic cholangiocarcinoma.
12
Angioimmunoblastic T-cell lymphoma confirmed by molecular signature (w/o confirmation rate was 20%). no mutations were found in other
peripheral T-cell lymphomas.
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